Clinical outcomes of intensive vs. less intensive first-line chemotherapy for metastatic colorectal cancer - supplementary material

dataset

posted on 2023-06-30, 08:38 authored by Kentaro Yamazaki, Satoshi Yuki, Eiji Oki, Fumikazu Sano, Misako Makishima, Kenichi Aoki, Tetsutaro Hamano, Kouji Yamamoto

Supplementary Materials

Figure S1. Subgroup analysis of (A) TFST and (B) OS between the IT and LIT groups. TFST, time to first subsequent therapy; OS, overall survival; IT, intensive therapy; LIT, less-intensive therapy; CI, confidence interval; HR, hazard ratio.

Figure S2. Subgroup analysis of (A) TFST and (B) OS between the with- and without-MTA groups. TFST, time to first subsequent therapy; OS, overall survival; w/o, without; w/, with; MTA, molecularly targeted agent; CI, confidence interval; HR, hazard ratio.

Figure S3. Subgroup analysis of (A) TFST and (B) OS between the with- and without-BEV groups. TFST, time to first subsequent therapy; OS, overall survival; w/o, without; w/, with; BEV, bevacizumab; CI, confidence interval; HR, hazard ratio.

Table Supplemental 1. Patient characteristics and Barthel index scores

Table Supplemental 2. Patient characteristics in the with- and without-molecularly targeted agent (MTA) subgroups.

Table Supplemental 3. Patient characteristics in the intensive therapy (IT) and less-intensive therapy (LIT) subgroups.